← SynDRA
LINAGLIPTIN
SynDRA canonical compound SYN0007646 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | DPP4 |
|---|
| Mechanism of action | Dipeptidyl peptidase inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
- DPP4
- CHRM1
- DPP IV
- DPP9
- FAP
- Fap
Mechanisms of action (all sources)
- Dipeptidyl peptidase inhibitor
- DPP4 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CHRM3
- GHSR
- ABCC2
- MC3R
- OPRK1
- OPRD1
- NR3C1
- NPY1R
- MLNR
- MC4R
- MAPK1
- PDE3A
- MAOA
- KCNH2
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- OPRM1
- PDE4D
- HRH3
- SLC22A8
- TBXA2R
- SLCO1B3
- SLCO1B1
- SLC6A4
- SLC6A3
- SLC6A2
- SLC29A1
- SLC22A6
- PGR
- SLC22A5
- SLC22A4
- SLC22A11
- PTGS2
- PREP
- POU2F2
- POU2F1
- HTR1A
- HRH1
Drug classes
- Dipeptidyl-Peptidase IV Inhibitors
- Enzyme Inhibitors
- Hormones
- Hypoglycemic Agents
- Incretins
- Protease Inhibitors
- Dipeptidyl Peptidase 4 Inhibitors
- Dipeptidyl Peptidase 4 Inhibitor
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- GLYXAMBI
- Glyxambi
- JENTADUETO
- JENTADUETO XR
- LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
- TRADJENTA
- TRIJARDY XR
- Tradjenta
- tradjenta
- BI-1356
- Linagliptine
- Linagliptina
- Trazenta
- BI-1356-BS
- BI-1356BS
- BI1356
- BS-1356-BS
- Linagliptin component of glyxambi
- Linagliptin component of jentadueto
- Linagliptin component of trijardy xr
- Trajenta
- Ondero
- Ondero (TN)
- BI 1356 BS
- BI 1356
- GLYXAMBI COMPONENT LINAGLIPTIN
- 3X29ZEJ4R2
- TRIJARDY XR COMPONENT LINAGLIPTIN
- linagliptine
- CHEBI:68610
- linagliptinum
- RefChem:5948
- A10BH05
- DTXCID801506661
- Linagliptin (BI-1356)
- MFCD14635356
- ione
Reported adverse events
- Lactic acidosis
- Hypersensitivity
- Pancreatitis
- Nasopharyngitis
- Cough
- Arthralgia
- Rhabdomyolysis
- Rash
Look up LINAGLIPTIN in the interactive SynDRA portal →